Blood Transfusion

Compatibility testing identifies ABO and Rh antigens on donor red cells and compares them with the patient’s blood. This helps laboratories avoid introducing red-cell antigens that the patient’s antibodies recognize as incompatible. Appropriate matching reduces the risk of agglutination, in which cells clump together, and hemolysis, in which red cells are destroyed after infusion.

A patient’s antibodies can bind to unfamiliar antigens carried by transfused red cells. That interaction may produce agglutination and hemolysis, disrupting the intended benefit of the transfusion and potentially compromising circulation. The biological importance of compatibility testing is therefore not simply identification of blood type; it is prevention of an immune reaction against donor cells.

Component selection matches the transfusion to the deficient function. Red blood cells support oxygen delivery, plasma contributes to clotting capacity, and platelets address reduced platelet counts. This approach allows treatment to target anemia, impaired clotting, or platelet deficiency rather than administering the same blood product for every clinical need.

Before infusion, laboratories determine blood-group compatibility, with particular attention to ABO and Rh antigens. Donated blood is also screened, and clinicians select the relevant component, such as red blood cells, plasma, or platelets. These preparation steps establish a safer basis for intravenous administration and align the product with the patient’s biological and clinical requirements.

The choice depends on the patient’s immediate need. Red blood cells may be selected when anemia or blood loss reduces oxygen delivery, whereas plasma is relevant when clotting capacity is impaired. Platelets may be used when platelet counts are reduced. The component-based approach also supports treatment during trauma, surgery, and blood disorders when different deficiencies can occur.

In trauma and surgery, transfusion can help address severe blood loss by restoring oxygen delivery or blood volume, while component therapy can also support clotting. For blood disorders, treatment may target anemia, impaired clotting, or reduced platelet counts. Intravenous administration, preceded by matching and screening, provides a controlled route for delivering the needed component.